Compare AKBA & ITRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKBA | ITRG |
|---|---|---|
| Founded | 2007 | 1997 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 729.1M | 780.9M |
| IPO Year | 2014 | N/A |
| Metric | AKBA | ITRG |
|---|---|---|
| Price | $1.43 | $4.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $6.25 | $4.13 |
| AVG Volume (30 Days) | ★ 2.9M | 2.1M |
| Earning Date | 03-12-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.08 |
| Revenue | ★ $225,071,000.00 | $219,125,000.00 |
| Revenue This Year | $52.38 | $965.93 |
| Revenue Next Year | $22.45 | $9.39 |
| P/E Ratio | ★ N/A | $56.15 |
| Revenue Growth | ★ 32.49 | N/A |
| 52 Week Low | $1.30 | $0.82 |
| 52 Week High | $4.08 | $4.69 |
| Indicator | AKBA | ITRG |
|---|---|---|
| Relative Strength Index (RSI) | 41.75 | 61.14 |
| Support Level | $1.30 | $4.12 |
| Resistance Level | $1.41 | $4.57 |
| Average True Range (ATR) | 0.07 | 0.24 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 37.88 | 88.00 |
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.